Search clinical trials for: sorafenib and cisplatin

Total 272564 results

Istituto Clinico Humanitas

Completed

BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas

Sarcoma, Soft Tissue

Italy
Bayer

Terminated

A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.

Carcinoma, Renal Cell

Italy, Spain, France, Austria, Poland, United Kingdom, Ireland
Masonic Cancer Center, University of Minnesota

Withdrawn

Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer

Cervical Cancer

United States
Bayer

Active, not recruiting

Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib (JPMS-DTC)

Thyroid Carcinoma

Japan
Bayer
ICON Clinical Research

Completed

Sorafenib Long Term Extension Program (STEP)

Neoplasms

Spain, Hong Kong, Canada, Germany, France, United States, United Kingdom, Taiwan, New Zealand, Australia, Belgium, China, Bulgaria, Italy, Colombia, Poland, Korea, Republic of, Brazil, Ukraine
Memorial Sloan Kettering Cancer Center
Mayo Clinic; Washington University School of Medicine; Astellas Pharma US, Inc.; University of Southern California and other collaborators

Completed

Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients

Hepatocellular Carcinoma

United States
Bayer

Completed

Sorafenib for Residue Disease After Resection With Curative Intent (SECURE)

Carcinoma, Hepatocellular

China
Bayer

Completed

Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients

Thyroid Carcinoma

Japan
Bayer

Completed

Sorafenib Dose Escalation in Renal Cell Carcinoma

Carcinoma, Renal Cell

Italy, France, Germany, United Kingdom, Poland
German Breast Group
Bayer

Completed

Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer (SOFIA)

Breast Cancer

Germany
Bayer

Completed

BAY43-9006 Phase II Study for Renal Cell Carcinoma

Carcinoma, Renal Cell

Japan
Bayer

Completed

Extension Program for Bay 43-9006

Metastasis | Neoplasm

Canada, Belgium, Germany, United States
Bayer

Completed

Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients

Neoplasms

United States
National Cancer Institute (NCI)

Completed

S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas

Sarcoma

United States
Bayer

Completed

Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)

Carcinoma, Renal Cell

China, Taiwan
Bayer

Completed

Long-term Extension From RCC Phase II (11515)

Carcinoma, Renal Cell

Japan
Bayer

Completed

A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ® (PONDIAC)

Carcinoma, Renal Cell | Carcinoma, Renal Cell (Advanced)

Belgium
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis

Liver Cancer

United States
Swedish Medical Center
Bayer; Amgen

Completed

Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma

Lung Cancer

United States
Bayer

Completed

Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of BAY 43-9006

Kidney Diseases
Bayer

Completed

Relative Bioavailability of Sorafenib Tablet for Oral Suspension

Biological Availability

Germany
Emory University
OSI Pharmaceuticals

Terminated

A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer

Liver Cancer

United States
Bayer

Completed

Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety (SORINT)

Carcinoma, Hepatocellular

Germany
Bayer

Completed

Regulatory Post Marketing Surveillance Study on Nexavar®

Carcinoma, Renal Cell | Carcinoma, Hepatocellular

Korea, Republic of
Bayer

Completed

Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan

Carcinoma, Hepatocellular

Japan
Bayer

Completed

An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma

Carcinoma, Renal Cell

Belgium, Italy, Spain, Germany, France, Netherlands, Switzerland, Poland, Sweden, United Kingdom, Denmark
Bayer

Terminated

Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.

Carcinoma, Renal Cell

United States
Bayer

Completed

INSIGHT - Post Marketing Surveillance (INSIGHT)

Carcinoma, Hepatocellular

Germany, Austria
Bayer

Completed

Sorafenib Gastric Cancer Asian Phase I Study

Gastric Cancer

Japan
Bayer
Amgen

Completed

Sorafenib/Docetaxel Dose Escalation Trial

Neoplasms

United States
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

Juvenile Myelomonocytic Leukemia | Recurrent Disease | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Childhood Solid Neoplasm | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia... and other conditions

United States, Canada
Bayer

Completed

Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib (GIDEON)

Carcinoma, Hepatocellular

Japan, China, Slovakia, Croatia, France, Hungary, Indonesia, Korea, Republic of, Malaysia, Singapore, Spain, Sweden, Thailand, Philippines, Colombia, Czech Republic, Hong Kong, Italy, Kazakhstan, Mexico, Romania, Russian Federation, Ukrain... and more
Bayer

Completed

Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy (STELLA)

Hepatocellular Carcinoma

Italy
Bayer
Onyx Therapeutics, Inc.

Completed

Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination

Neoplasms

Germany, France
Bayer

Completed

A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC). (MISSION)

Carcinoma | Non-Small-Cell Lung

Italy, Spain, China, Korea, Republic of, Bulgaria, Turkey, Greece, Philippines, Taiwan, Russian Federation, Hungary, Singapore, France, Netherlands, Sweden, Belgium, United States, Austria, Thailand, Germany, Israel, Poland, Canada, United... and more
Gesellschaft fur Medizinische Innovation - Hamatologie...
iOMEDICO AG

Completed

Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment (PASO)

Metastatic Breast Cancer

Germany
Second Affiliated Hospital of Guangzhou Medical...

Completed

TACE Combined With Sorafenib and Tislelizumab for Advanced HCC

Hepatocellular Carcinoma Non-resectable

China
Peking University Cancer Hospital & Institute

Unknown

HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma

Melanoma

China
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Patients With Metastatic Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

United States
National Cancer Institute (NCI)

Completed

A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer

Prostate Cancer

United States
Bayer
Amgen

Completed

Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer

Carcinoma, Renal Cell

United States, United Kingdom
Bayer

Completed

Hepatic Impairment Study

Liver Disease

United States
Bayer

Completed

Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid Tumors

Neoplasms

United States
Bayer

Completed

BAY43-9006 - Phase II in Advanced Breast Cancer

Breast Cancer | Breast Neoplasms

Italy, Germany
Castleton University

Withdrawn

Cannabidiol Effects on Cardiovascular System and Exercise Responses

Healthy

United States
Ohio State University Comprehensive Cancer Center
National Comprehensive Cancer Network

Completed

Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Tongue Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous... and other conditions

United States
Sinocelltech Ltd.

Active, not recruiting

SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

China
Mina Alpha Limited

Active, not recruiting

First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer (OUTREACH)

Hepatocellular Carcinoma | Liver Cancer

Taiwan, Singapore, United Kingdom
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Advanced Adult Hepatocellular Carcinoma

United States
Memorial Sloan Kettering Cancer Center
Bayer

Completed

Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer

Esophageal Cancer | Gastroesophageal Junction Cancer

United States

Search clinical trials for: sorafenib and cisplatin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations